SCHEMBL19458941

SCHEMBL19458941

Nc1ccc(-c2cc3c(N4CCN(C5(C=O)CC5)CC4)ccnn3c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.37
MAP4K4 O95819 2/20 0.32
RET P07949 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19459017 0.83 KIT (0.39) KITRET
SCHEMBL19462890 0.77 RET (0.45) KITMAP4K4RET
SCHEMBL21678301 0.76 KIT (0.38) KITRET
SCHEMBL21679943 0.75 KIT (0.40) KITMAP4K4RET
SCHEMBL19458940 0.74 ALDH1A1 (0.44) KITRET
SCHEMBL19486444 0.73 KIT (0.42) KITMAP4K4RET
SCHEMBL25767185 0.70 CHRNA7 (0.36) KITMAP4K4
SCHEMBL19491029 0.69 KIT (0.33) KITRET
SCHEMBL19486329 0.69 CHRNA7 (0.44) KITMAP4K4
SCHEMBL19486469 0.68 BMP4 (0.46) KITMAP4K4RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 27/4885MAP4K4 439/4885RET 56/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 KIT 189/4885MAP4K4 312/4885RET 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.